With a new CEO tapped to drive EuroAPI’s turnaround, the Sanofi spinoff is proposing drastic steps to get its business on track, including potential layoffs and site closures.
Overseeing the four-year plan, dubbed FOCUS-27, will be new chief executive Ludwig de Mot—an industry veteran with a track record at “companies undergoing transformation,” EuroAPI said in an earnings release Wednesday. De Mot, who will take up the reins on Friday, joined the company in January as EuroAPI’s chief transformation officer.
The restructuring news comes as EuroAPI reported net sales growth of nearly 4% to 1.01 billion euros (about $1.09 billion) in 2023.
While the company’s 2023 financial results show revenue growth, EuroAPI’s losses have ballooned, likely providing the rationale behind its reorganization initiative. Last year, the company reported a net loss of 189.7 million euros, up more than 10-fold compared with 15 million euros in 2022.
EuroAPI said its reorganization project will include streamlining its active pharmaceutical ingredients portfolio, becoming a more “focused” contract development and manufacturing organization, developing a “rationalized” industrial footprint and transforming into a “leaner organization.”
To that last point, EuroAPI warned that “all functions,” including industrial operations, quality, R&D and support functions, will contribute to the cost-saving initiative through potential layoffs.
As for its industrial footprint, EuroAPI says planned moves—which will impact its site in Frankfurt, Germany, and could lead to two other workshops being “mothballed”—will allow the company to boost its capacity utilization up to an average rate of 80% to 85%. Further, as part of EuroAPI’s focus on higher-value APIs, the company is weighing whether to divest its sites in Haverhill, England, and Brindisi, Italy.
Regarding its API portfolio, EuroAPI will refocus its efforts around ostensibly more profitable drug ingredients for large molecules. The company is discontinuing 13 APIs with “low or negative margins,” including certain complex small molecules produced in Frankfurt and Brindisi.
EuroAPI figures that its contract manufacturing business will remain its biggest growth driver, and, to make sure it reaches its full potential, the company said it will begin shifting its portfolio toward more “customized and high-value CDMO segments.” The goal is to focus on large biotech and big pharma companies, EuroAPI said, adding that it wants to take on more late-stage projects, too.
Last year, EuroAPI’s CDMO sales grew 6.8% to 285.8 million euros (about $309.7 million). The company noted that beyond Sanofi, its CDMO business has accumulated a Rolodex of more than 500 customers.
EuroAPI’s board kicked off a strategic review last fall, around the same time the company slashed its projected revenue and earnings growth for 2023. At the time, then-CEO Karl Rotthier attributed the changes to pricing pressures from lower inflation, certain customers’ inventory reduction programs and the greater “biotech funding crisis.” He noted that more than 20 of the company’s projects had been delayed, reduced in scope or halted altogether.
As part of the strategic review, the board determined Rotthier would step down on Oct. 30 after helming the drug ingredients business since 2021, when it was still a part of Sanofi.
EuroAPI is just one of several biopharma companies undergoing significant changes.
Protein-based COVID shot maker Novavax, for instance, last year laid off 30% of its workforce amid a restructuring scheme. Elsewhere, OTC self-care specialist Perrigo recently unveiled its own restructuring initiative dubbed Project Energize, which will see it trim roughly 6% of its staff, or hundreds of workers.
By Fraiser Kansteiner
Source: fiercepharma.com
Bristol Myers Squibb (BMS) and Chinese biopharma company Hengrui Pharma have inked one of the largest licensing and collaboration deals in the industry’s history, centering around several early-stage oncology, immunology and haematology assets.
The appointment marks a planned transition in leadership structure to continue to build on the company’s success. A combination of organic growth and targeted acquisitions has led Symeres to evolve into a fully integrated transatlantic partner.
Sun Pharma’s recent, nearly $12 billion acquisition reflects growing global ambitions of India’s pharma industry to evolve from its roots in the generics market. But is the country poised for a China-esque pivot toward becoming a powerhouse of innovation?
